Dr. Hammers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-645-2542- Is this information wrong?
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2005 - 2009- Johns Hopkins University/Bayview Medical CenterResidency, Internal Medicine, 2002 - 2005
Certifications & Licensure
TX State Medical License 2016 - 2024
MD State Medical License 2009 - 2022
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy Start of enrollment: 2015 Mar 28
- SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients Start of enrollment: 2017 Mar 01
Publications & Presentations
PubMed
- 1 citationsImmunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma.Singla, N., Nirschl, T., Obradovic, A., Shenderov, E., Lombardo, K., Liu, X., Pons, A., Zarif, J., Rowe, S., Trock, B., Hammers, H., Bivalacqua, T., Pierorazio, P., De...> ;Scientific Reports. 2024 Jan 17
- The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023.Lewis, B., Poteat, S., Pels, K., Choueiri, T., Pal, S., Hammers, H.> ;The Oncologist. 2024 Feb 2
- 2 citationsPhase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, David F McDermott, Mehmet A Bilen, Mark Stein, Jeffrey A Sosman, Robert Alter, Elizabeth R Plimack, Moshe C Ornstein,...> ;Journal for Immunotherapy of Cancer. 2023 Mar 1
- Join now to see all
Press Mentions
National Cancer Institute Renews $11.5 Million Program of Excellence Award in Kidney CancerSeptember 19th, 2022
UT Southwestern Develops Test to Predict Immunotherapy Response in Kidney CancerJune 4th, 2019
Kccure Applauds Fda Approval of New Combination Therapy for Advanced Kidney CancerApril 22nd, 2019- Join now to see all
Professional Memberships
- Member
- Member
Other Languages
- German
Hospital Affiliations
University of Texas Southwestern Medical CenterDallas, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
